Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • Exagen's Change in Accured Expenses rose 9699.5% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 30373.25%. This contributed to the annual value of $600000.0 for FY2024, which is 7597.12% down from last year.
  • Latest data reveals that Exagen reported Change in Accured Expenses of $1.2 million as of Q3 2025, which was up 9699.5% from -$192000.0 recorded in Q2 2025.
  • Over the past 5 years, Exagen's Change in Accured Expenses peaked at $1.7 million during Q4 2024, and registered a low of -$1.4 million during Q1 2024.
  • In the last 5 years, Exagen's Change in Accured Expenses had a median value of $154000.0 in 2021 and averaged $118368.4.
  • Per our database at Business Quant, Exagen's Change in Accured Expenses plummeted by 64545.45% in 2022 and then skyrocketed by 90337.08% in 2023.
  • Over the past 5 years, Exagen's Change in Accured Expenses (Quarter) stood at $446000.0 in 2021, then plummeted by 387.22% to -$1.3 million in 2022, then soared by 138.8% to $497000.0 in 2023, then surged by 250.1% to $1.7 million in 2024, then tumbled by 32.18% to $1.2 million in 2025.
  • Its Change in Accured Expenses was $1.2 million in Q3 2025, compared to -$192000.0 in Q2 2025 and -$1.4 million in Q1 2025.